Doximity Raises FY Outlook, Guides Q2 Above Consensus; Shares Surge 74%
DOCS has more than doubled off its 52-week low of $17.15 on elevated volume (4.9× avg).
Summary
Doximity raised its full-year revenue guidance to $671M-$681M from $664M-$676M, and issued Q2 guidance of $170M-$171M, slightly below consensus but signaling confidence. The stock surged 74% after hours, recovering from a 53% year-to-date decline. Q1 revenue of $156.6M beat estimates by $4.8M, driven by a 30% jump in workflow active prescribers and a 25% sequential increase in AI search queries. Profit halved to $24.3M as AI spending surged, but the market is rewarding the top-line momentum and raised outlook. This follows the earlier Q1 report that highlighted the profit decline; the new guidance and operational metrics provide a clearer growth narrative.
At the time of this announcement, DOCS was trading at $36.85 on NYSE in the Technology sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $17.15 to $76.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.